medigraphic.com
ISSN 1028-4818 (Electronic)

2015, Number 3

<< Back Next >>

Mul Med 2015; 19 (3)

Frequency and factors related to the presence of ischemic cardiopathy in type II diabetes mellitus patients

R Valdés RER, Bencosme RN, Morales VB

Language: Spanish
References: 28
Page: 1-15
PDF size: 205.13 Kb.


ABSTRACT

Introduction: the amount of persons with diabetes mellitus (DM) has dramatically increased in the last years, becoming a worldwide health problem.
Objective: to determine the frequency and factors related to the presence of ischemic cardiopathy in people with type II diabetes mellitus.
Method: it was performed a transverse and descriptive study with 1005 patients hospitalized in the Diabetic Care Center of Bayamo, Granma in the period between September 2008 to June 2011.
Results: from the amount of the studied cases, 108 (10, 7 %) presented ischemic cardiopathy. In the uni-varied analysis it was observed that hypertension ( OR: 4,61, IC: 2.4-8.5, p 0,0000 ), women´s age ≥ 55 and men ≥ 45 years ( OR: 4,38, IC:2.5-7.5, p 0,0000 ), the hypertriglyceridemia ( OR: 2,44, IC: 1.5-3.8, p 0,0001 ), the metabolic syndrome ( OR:2,39, IC:1.4-3.9, p 0,0005 ) and hypercholesterolemia ( OR: 2,25, IC: 1.5-3.3, p 0,0001 ) were significantly associated with the development of the ischemic cardiopathy.
Conclusions: the ischemic cardiopathy is a frequent complication in the people with type II diabetes mellitus, and the factors with a greater influence in its development are: hypertension, the age (in women ≥ 55 and in men ≥ 45 years), the dyslipidemia and the metabolic syndrome.


REFERENCES

  1. Department of Health and Human Services. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA, U.S.: Centers for Disease Control and Prevention; 2011.

  2. International Diabetes Federation. The IDF Diabetes Atlas. Brussels: International Diabetes Federation; 2011.

  3. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care [Internet]. 2009 [citado 20 de mayo de 2015]; 32(suppl 1): S13-61. Disponible en: http://care.diabetesjournals.org/content/32/Supplement_1/S13.long

  4. Méndez JD, Xie J, Aguilar M, Méndez V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem [Internet]. 2010 [citado 15 Jun 2010]; 341(1-2): 33- 41. Disponible en: http://www.springerlink.com/content/wmg173j7w459u483/

  5. Cooper-Dehoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA [Internet]. 2010 [citado 20 de mayo de 2015]; 304 (1):61-8. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=186169

  6. Cuba. Ministerio de Salud Pública. Informe anual del departamento de enfermedades crónicas no trasmisibles. Dirección Provincial de Higiene y Epidemiología. La Habana: MINSAP; 2011.

  7. World Health Organization. Definition and classification of diabetes mellitus and complications. Report of WHO consultation. Part 1: Diagnosis and classification of Diabetes mellitus. Genova: WHO; 1999.

  8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003; 289: 2560-72.

  9. World Health Organization. Expert Committee Phycal Status. The use and interpretation of anthropometry. Geneva: WHO; 1995.

  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA [Internet]. 2001[citado 20 demayo de 2015]; 285: 2486-97. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=193847

  11. Campos Nodarse A, Dueñas Herrera A, Espinosa Brito A, Herrera Gozález A, Nasiff Hadad A, et al. Primer consenso cubano de dislipoproteinemias: Guía para la prevención, detección, diagnóstico y tratamiento. Rev Cubana Endocrinol [Internet]. 2006 [citado 20 de Mayo de 2015]; 17 (4): 1-31. Disponible en: http://bvs.sld.cu/revistas/end/vol17_4_06/end01406.htm

  12. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care [Internet]. 2007 [citado 20 demayo de2015]; 30: 162 - 72. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17192355

  13. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care [Internet]. 2010 [citado 20 de mayo de 2015]; 33(2):442-9. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809299/

  14. Valdés Ramos E, Bencosme Rodríguez N. Las complicaciones macrovasculares y su relación con algunas variables clínicas y bioquímicas en diabéticos tipo 2. Rev Cubana Endocrinol [Internet]. 2010 Dic [citado 2012 Ene 14]; 21(3): 256-68. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532010000300001&lng=es&nrm=iso&tlng=es

  15. Valdés Ramos ER, Rivera Chávez M, Bencosme Rodríguez N. Comportamiento del infarto agudo del miocardio en personas con diabetes mellitus de la provincia Granma. Rev Cubana Endocrinol [Internet]. 2012 Ago [citado 2012 Nov 25]; 23(2): 128-138. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532012000200003&lng=es.

  16. Díaz Díaz O, Valenciaga Rodríguez JL, Domínguez Alonso E. Características clínicas de la diabetes mellitus tipo 2 en el municipio de Güines: Año 2002. Rev Cubana Endocrinol [Internet]. 2003 Abr [citado 2015 Mayo 21]; 14(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532003000100005&lng=es.

  17. Agramonte Martínez M. Prevalencia de factores de riesgo de la aterosclerosis en pacientes diabéticos tipo 2. Rev Haban Cienc Méd [Internet]. 2009 Nov [citado 2015 Mayo 21] ; 8(4):. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2009000400007&lng=es

  18. Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J [Internet]. 2008 [citado 21 de mayo de 2015]; 29: 1316-26. Disponible en: http://ficheros.publico.es/resources/archivos/2008/2/5/1202230624495EHJ.pdf

  19. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care Ìnternet]. 2010 [citado 21 de mayo de 2015]; 33: 442–9. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809299/

  20. Valdés Ramos E, Bencosme Rodríguez N. Frecuencia de la hipertensión arterial y su relación con algunas variables clínicas en pacientes con diabetes mellitus tipo 2. Rev Cubana Endocrinol [Internet]. 2009 Dic [citado 2012 Nov 25]; 20(3): 77-88. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532009000300002&lng=es.

  21. Licea Puig ME, Singh Linares O, Smith Limonta A, Martínez García R. Frecuencia, características clínicas y resultados terapéuticos de la hipertensión arterial en diabéticos tipo 2 de un área de salud. Rev Cubana Endocrinol [Internet]. 2002 Ago [citado 2015 Mayo 21]; 13(2): 1561. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532002000200007&lng=es.

  22. Cooper-Dehoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA [Internet]. 2010 [citado 21 de mayo de 2015]; 304: 61-8. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=186169

  23. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet [Internet]. 2008 [citado 21 de mayo de 2015]; 371(9607): 117-25. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18191683

  24. Norderstgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting tryglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA [Internet]. 2007 [citado 21 de mayo de 2015]; 298; 299-308. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=208012

  25. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol [Internet]. 2007 [citado 21 de mayo de 2015]; 99:6-14. Disponible en: http://www.sciencedirect.com/science/article/pii/S000291490602193X

  26. Peripheral arterial disease in the elderly: recognition and management. Am J Cardiovasc Drugs [Internet]. 2008 [citado 21 de mayo de 2015]; 8: 353-64. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19159122

  27. Dueñas Herrera A, Armas Rojas NB, Noval García R, Turcios Tristá SE, Milián Hernández A, Cabalé Vilariño MB. Riesgo cardiovascular total en los trabajadores del Hotel "Meliá Cohíba. Rev Cubana Endocrinol [Internet]. 2008 Abr [citado 2012 Dic 03]; 19(1):. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1561-29532008000100003&script=sci_arttext

  28. Hernández I, Romero PJ, González JM, Romero A, Ruiz MJ. Tabaquismo en la mujer. Revisión y estrategias futuras. Prev Tab [Internet]. 2000 [citado 21 de mayo de 2015]; 2(1): 45-54. Disponible en: http://www.bvsde.paho.org/bvsacd/cd37/pt21p45.pdf




2020     |     www.medigraphic.com